Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis.
Pulm Circ
; 4(2): 342-5, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-25006453
ABSTRACT
Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet-derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Pulm Circ
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Austrália